New Long-Lasting HIV prevention shots tested for safety
NCT ID NCT06033547
Summary
This early-stage study tested the safety and how the body processes two new long-acting injection formulations of cabotegravir, a medication used for HIV prevention. The study involved 56 healthy adult volunteers who received a single injection. Researchers monitored participants for side effects and measured how long the medication stayed in their bodies to understand if these new formulations could work for future HIV prevention.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.